MyNeo Personalized Therapy | About us
240
page-template,page-template-full_width,page-template-full_width-php,page,page-id-240,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.6,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

The MyNeo Team

Be one of us!

Wim Van Criekinge

Bio

Wim Van Criekinge Ph.D. is a tenured professor at the University of Ghent. He founded and heads the laboratory for computational genomics and bioinformatics (BIOBIX) as well as the core sequencing facility (NXTGNT) with global collaborative reach across applied bioscience and clinical discovery. Wim’s lab was the first to employ routine whole epigenomics sequencing at scale in pursuit of diagnostic discovery and his lab has published results in nearly 200 peer-reviewed papers.

 

Wim has successfully applied his knowledge in bioinformatics, (epi)genetics and diagnostics through extensive collaborations as well as in founding innovative start-ups that resulted in successful exits (Devgen, Genohm, etc. ). He currently serves as the CSO of MDxHealth, a public biotech company with a focus on uro-oncology. Wim holds a Master’s degree in Chemical Engineering from the University of Ghent, Belgium, where he also earned his Ph.D. in Molecular Biology in 1998.

Work
2005-PRESENT: CSO, MDXHEALTH INC, IRVINE

 

Epigenetics is a key layer of biology that will have ramifications far beyond basic science into diagnostics and therapeutics. Epigenetic editing allows for cellular (re)programming and will be instrumental in reverting many different disease phenotypes. Within MDxHealth different molecular methodologies have matured including almost all flavours of sequencing technologies. We collaborate with pioneers in the field, published more than 100 peer-reviewed papers and were the first to sequence epigenome-wide on a routine basis. CSO responsibilities include managing high profile academic contracts and projects to support the successful market introduction of both clinical diagnostics (Prostate ConfirmMDx) and companion diagnostics (Brain Predictive MDx).

 

2002-PRESENT: PROFESSOR COMPUTATIONAL GENOMICS & BIOINFORMATICS, GHENT, BELGIUM

 

BIOBIX was founded at the faculty of bioengineering in fall 2002 as bioinformatics evolved from a service discipline that merely assisted the lab to a central core asset. This transition requires a multidisciplinary approach where people are trained with a strong formal background in both applied sciences, informatics and math/statistics. The core competences of BIOBIX are data-integration and analysis, particularly in combination with high-throughput applications. Based on these competences, BIOBIX obtained ample expertise in epigenetic research, more specifically DNA-methylation and telomere length profiling, but also histone modification and non-coding RNA analyses. Within BIOBIX there is a general focus on systems biology and comparative genomics reflected in different supported technologies: next-generation sequencing, NMR-based metabonomics, MS-based proteomics, proteogenomics, transcriptomics, phylogenetic footprinting, heterogenous data-integration statistics, ncRNA detection and target prediction, selection of novel targets. These technologies are applied in many different disease areas, but with cancer and (cardiovascular) aging as two most important targets. BIOBIX also extensive IT knowledge in setting up high-performance computing environments and is one of the few European labs actively mirroring all available sequence data on dedicated hardware using in-house software.

 

2008-PRESENT: FOUNDER & CHAIRMAN, NXT-GNT, GHENT, BELGIUM

 

Next-generation sequencing machines and analysis pipelines have applications in many life science areas. NXT-GNT allows consolidating our front running positions in workflow development while enlarging the scope of applications.

 

2002 – 2018: CO-FOUNDER/DIRECTOR/CHAIRMAN OF GENOHM SA

 

Originally founded in Ghent (Belgium) in 2002 as a small two-person bio-informatics shop, Genohm re-established itself in 2011 as an EPFL Start-Up at the Innovation Park in Lausanne (Switzerland). With the successful launch of its main laboratory software automation suite, SLIMS, Genohm officially entered the lab informatics market, proudly serving a rapidly growing set of customers in widely varying research and clinical environments throughout Europe, the Middle East, Asia Pacific, and the US. Today, Genohm has offices in Lausanne, Ghent, and Durham NC and counts a workforce of 40+ highly trained software and life sciences engineers. The company was acquired by Agilent Technologies in 2018.
www.genomeweb.com

 

1998-2001: FOUNDER & DIRECTOR, DEVGEN NV, GHENT, BELGIUM

 

Devgen was founded as a spin-off of Ghent University and The Flemish Institute for Biotechnology in 1997 to commercialize intellectual property it licensed on the use of RNAi in nematodes and its use for screening for therapeutics and/or their targets. Its work focused on the nematode C. elegans as a model system, which functions as a model for human diseases, but also as a model for the kind of nematodes that are agricultural pests. The company raised 37 million Euro in its first three years, first from the GIMV and Abingworth investment companies at its launch, then from the IWT, then from another round of private investors including ING, KBC, Life Science Partners, Sofindex, Rendex, and Mercator, then from Polytechnos and Capricorn. In September 2012, Syngenta placed a bid for the acquisition of Devgen as part of a wave of large ag companies buying biotech companies. Devgen’s shares were delisted from the NYSE in February 2013 and the acquisition was completed in December 2013.

Education

UGENT (University of Ghent), Ghent (Belgium) – Post-doctoral degree in Knowledge Technology 1997
BIRCKBECK COLLEGE (University of London), London (UK) – Post-doctoral degree in Protein Structure 1997
UGENT (University of Ghent), Ghent (Belgium) – Ph.D., “Characterisation of caspases in a “2- en 3-hybrid”-system” 1997
UGENT (University of Ghent), Ghent (Belgium) – Master in Bioengineering, Maxima Cum Laude 1994
ENSCM (Ecole Nationale Superiere de Chimie), Montpellier (France) – MS, Greatest Distinction 1993

Jan Van den Berghe

Work
2008 – PRESENT: FOUNDER, CHAIRMAN & CFO OF LIPA HOLDING NV

 

Based in Bavegem, Belgium. Acquired more than 20 companies to build the group into a diversified food and food recycling conglomerate: Lipa produces baking ingredients and high-quality fats and oils for the food industry and catering sector. Lipa also collects organic waste streams and processes those raw materials into high-quality animal and plant fats and proteins. At present, Lipa has about 200 FTE and >80M EUR turnover.
lipafamily.be

 

2002 – 2018: CO-FOUNDER/DIRECTOR/CHAIRMAN OF GENOHM SA

 

Originally founded in Ghent (Belgium) in 2002 as a small two-person bio-informatics shop, Genohm re-established itself in 2011 as an EPFL Start-Up at the Innovation Park in Lausanne (Switzerland). With the successful launch of its main laboratory software automation suite, SLIMS, Genohm officially entered the lab informatics market, proudly serving a rapidly growing set of customers in widely varying research and clinical environments throughout Europe, the Middle East, Asia Pacific, and the US. Today, Genohm has offices in Lausanne, Ghent, and Durham NC and counts a workforce of 40+ highly trained software and life sciences engineers. The company was acquired by Agilent Technologies in 2018.
www.genomeweb.com

 

2002 – 2017: DIRECTOR / CHAIRMAN OF OYSTERSHELL NV

 

Based in Ghent, Belgium. Oystershell laboratories is a world-class developer of innovative consumer healthcare products and is especially acknowledged for its success in the anti-lice and insects category, its new skin treatments such as for warts and several other important contributions to OTC pharma. The innovative product portfolio combines own brands and regional distribution agreements with major OTC players. The company was acquired by Gilde Buy-Out Partners in 2017.
gilde.com/news

 

PREVIOUSLY:

 

Independent strategy consultant, co-founder & CFO of smarterwork.com, (senior) consultant for the Boston consulting group.

Education

INSEAD (Fontainebleau, France) – Master in Business Administration 1998 – 1999
VLERICK Business School (Ghent, Belgium) – Master in General Management 1994 – 1995
UGENT (University of Ghent), Ghent (Belgium) – Master in Bioengineering, Magna Cum Laude 1989 – 1994
Fachhochschule für Technik Mannheim (Germany) – Master in Chemistry (Erasmus; 6m), Magna Cum Laude 1992

Cedric Bogaert

Work
2017 – 2019: ARCHITECTURAL LEAD ACCENTURE

 

Accenture has been doing major business transformations globally and is amongst the top consultancy companies. During my Accenture employment, I became familiar with CRM software implementation, and obtained three certifications in that process: Apttus CPQ, Apttus CLM and Salesforce Administrator. I followed two external approach thinking types of trainings (Agile and DevOps), that brought me in line with the operational excellence core at Accenture.
I’ve also taken part in the Life Sciences Industry Certification Program, which provides an organized and effective channel to enhance business skills in the Life Sciences industry. Via multiple training sessions, experts provided insights into pharmaceutical Business Strategies, R&D, Supply Chains, Sales & Marketing and into the predicted future trends in the life science industry.
My largest assignment was at a globally leading food & beverage producer with the headquarters located in the Netherlands. As I gained more insights into the complete end-to-end pricing scheme of the client. As a pricing architectural lead, I’d taken ownership of the pricing subject and all process streams related to it. This meant among others fine-tuning the pricing foundation for optimizing process performance and company profitability.

 

2016-2017: BIOINFORMATICIAN LMCT IMMUNOLOGICAL LAB

 

The LMCT research lab is largely focused on immunology and is supervised by prof. MD. Kris Thielemans. During my employment as a bioinformatician, I was responsible for analysing the input stream of data delivered by the research team and advising the next steps in the trials.

 

2015 – 2016: UGENT RESEARCH

 

The thesis “epigenetic effects of menohop” started out as a small medical project, but quickly grew as the potential of the project was conceived by many others. The result was a 3-year medical/bio-informatics project involving a multi-university collaboration. General effects of our diet on the epigenome was in-vitro analysed in human cancer cell lines, and the effects of these epigenetic mutations were predicted. Menohop is a dietary supplement taken by a large percentage of women experiencing menopausal symptoms. Due to the low doses of phytoestrogen in these supplements, effects on the epigenome were investigated in a dose-response correlation. Multiple pathways were written to visually select interesting silenced/enhanced genes after the treatment with the nutritional elements. Both specific bisulfite sequencing and general 450K sequencing were used during this research.

Education

UGENT (University of Ghent), Ghent (Belgium) – Master in Bioengineering, Magna Cum Laude
HELSINGIN YLIOPISTO (University of Helsinki) – Master in Medical Genetics (Erasmus; 6m), Summa Cum Laude